Vertex Pharmaceuticals (VRTX) 재무상태표
NASDAQ · Healthcare · Biotechnology · 직원 6,400명 · CEO Reshma Kewalramani
- 주가
- $558.88 +3.50%
- 시가총액
- $1420억
- 기업가치
- $1370억
- 최근 실적
- Q2 '26 2026-08-04 제출
- 다음 실적
- 2026-11-02 EPS 추정 $4.82
Vertex Pharmaceuticals (VRTX)의 Q2 '26말 현금 및 단기투자는 $78.5억, 리스 포함 차입금은 $19.8억입니다. 자산총계 $274억, 부채총계 $71.8억, 주주지분 $202억.
재무상태표
| 재무상태표 | 추세 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 자산 | |||||||||||||
| 현금 및 현금성자산 | $111억 | $104억 | $91.6억 | $45.8억 | $52.4억 | $45.7억 | $46.7억 | $49.7억 | $49.4억 | $50.9억 | $54.9억 | $61.4억 | |
| 단기투자 | $8.18억 | $8.49억 | $10.1억 | $12.2억 | $12.9억 | $15.5억 | $15.3억 | $14.1억 | $13.5억 | $15.2억 | $17.5억 | $17.1억 | |
| 매출채권 | $15.4억 | $15.6억 | $17.9억 | $16.6억 | $17.5억 | $16.1억 | $18.1억 | $18.9억 | $19.5억 | $20.5억 | $20억 | $21.3억 | |
| 재고자산 | $6.89억 | $7.39억 | $8.13억 | $9.15억 | $10.8억 | $12.1억 | $13.6억 | $15억 | $16.3억 | $16.9억 | $17.7억 | $17.7억 | |
| 기타 유동자산 | $5.4억 | $8610만 | $5.11억 | $5.75억 | $4.49억 | $2.07억 | $6.43억 | $6.52억 | $7.09억 | $7.49억 | $7.21억 | $0 | |
| 유동자산 | $147억 | $141억 | $133억 | $89.4억 | $98억 | $96억 | $100억 | $104억 | $106억 | $112억 | $117억 | $125억 | |
| 유형자산(순액) | $14.3억 | $14.5억 | $14.9억 | $17.7억 | $25.1억 | $25.8억 | $26.3억 | $26.5억 | $30.2억 | $30.8억 | $16.1억 | $33.3억 | |
| 장기투자 | $17억 | $25억 | $43.8억 | $43.9억 | $47억 | $51.1억 | $51.6억 | $56.5억 | $57.2억 | $58.1억 | $57.5억 | $57.9억 | |
| 영업권 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | |
| 무형자산 | $6.04억 | $8.4억 | $8.35억 | $8.38억 | $8.32억 | $8.26억 | $4.41억 | $4.36억 | $4.3억 | $4.24억 | $4.19억 | $4.13억 | |
| 이연법인세자산 | $17.3억 | $18.1억 | $19.6억 | $21.9억 | $23.1억 | $23.3억 | $25.4억 | $27.1억 | $29.4억 | $34억 | $29.5억 | $30.1억 | |
| 기타 비유동자산 | $4.75억 | $8.95억 | $8.76억 | $9.16억 | $9.9억 | $9.99억 | $10.1억 | $10.8억 | $11억 | $11.4억 | $29.4억 | $12.5억 | |
| 비유동자산 | $70.3억 | $85.9억 | $106억 | $112억 | $124억 | $129억 | $129억 | $136억 | $143억 | $149억 | $148억 | $149억 | |
| 자산총계 | $217억 | $227억 | $239억 | $201억 | $222억 | $225억 | $229억 | $240억 | $249억 | $261억 | $265억 | $274억 | |
| 부채 | |||||||||||||
| 매입채무 | $3.76억 | $3.65억 | $3.51억 | $3.28억 | $3.96억 | $4.13억 | $4.45억 | $4.42억 | $4.2억 | $4.62억 | $4.89억 | $4.3억 | |
| 미지급비용 | $29.1억 | $23.2억 | $28억 | $29.4억 | $32.2억 | $23.6억 | $29.5억 | $32.7억 | $36.1억 | $3.98억 | $29.8억 | $31.8억 | |
| 단기차입금 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $8280만 | $0 | $0 | |
| 미지급세금 | $0 | $9950만 | $0 | $0 | $0 | $1.61억 | $0 | $0 | $0 | $0 | $0 | $0 | |
| 이연수익 | $0 | $1.7억 | $0 | $0 | $0 | $2.07억 | $0 | $0 | $0 | $1.72억 | $0 | $0 | |
| 기타 유동부채 | $3.16억 | $5070만 | $6.49억 | $2.79억 | $3.58억 | $3140만 | $3.86억 | $4.25억 | $4.42억 | $27.5억 | $4.07억 | $3.29억 | |
| 유동부채 | $36억 | $35.5억 | $38억 | $35.5억 | $39.7억 | $35.6억 | $37.8억 | $41.4억 | $44.8억 | $38.6억 | $38.8억 | $39.4억 | |
| 장기차입금 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $18.5억 | $0 | $0 | |
| 리스부채(비유동) | $7.45억 | $7.25억 | $7.21억 | $9.33억 | $17억 | $16.6억 | $16.5억 | $15.3억 | $18.3억 | $19.5억 | $19.9억 | $19.8억 | |
| 이연법인세부채 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $13.1억 | $0 | $0 | |
| 기타 비유동부채 | $8.69억 | $8.78억 | $8.54억 | $8.77억 | $9.33억 | $9.02억 | $9.52억 | $12억 | $12.3억 | -$14.9억 | $12.6억 | $12.6억 | |
| 비유동부채 | $16.1억 | $16억 | $15.7억 | $18.1억 | $26.4억 | $25.6억 | $26억 | $27.2억 | $30.7억 | $36.2억 | $32.4억 | $32.4억 | |
| 부채총계 | $52.1억 | $51.5억 | $53.7억 | $53.6억 | $66.1억 | $61.2억 | $63.8억 | $68.6억 | $75.4억 | $74.8억 | $71.2억 | $71.8억 | |
| 자본 | |||||||||||||
| 보통주 및 주식발행초과금 | $260만 | $260만 | $260만 | $260만 | $260만 | $260만 | $260만 | $260만 | $250만 | $250만 | $250만 | $250만 | |
| 이익잉여금 | $91.7억 | $101억 | $112억 | $76.5억 | $86.9억 | $96.1억 | $103억 | $113억 | $124억 | $136억 | $146억 | $157억 | |
| 기타포괄손익누계액 | -$300만 | -$1430만 | $1730만 | $2250만 | $2880만 | $1.28억 | $6810만 | -$1.01억 | -$6450만 | -$1590만 | $2480만 | $4850만 | |
| 주주지분 | $165억 | $176억 | $185억 | $148억 | $156억 | $164억 | $165억 | $172억 | $173억 | $187억 | $194억 | $202억 | |
| 부채(차입) | |||||||||||||
| 총차입금(리스 포함) | $7.45억 | $8.08억 | $7.21억 | $9.33억 | $17억 | $17.5억 | $16.5억 | $15.3억 | $18.3억 | $38.8억 | $19.9억 | $19.8억 | |
| 순차입금(차입금 - 현금) | -$104억 | -$95.6억 | -$84.4억 | -$36.5억 | -$35.4억 | -$28.2억 | -$30.3억 | -$34.4억 | -$31억 | -$12.1억 | -$35.1억 | -$41.7억 | |
| 재무상태표 | 추세 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 자산 | |||||||||||
| 현금 및 현금성자산 | $11.8억 | $16.7억 | $26.5억 | $31.1억 | $59.9억 | $68억 | $105억 | $104억 | $45.7억 | $50.9억 | |
| 단기투자 | $2.51억 | $4.23억 | $5.18억 | $6.99억 | $6.71억 | $7.3억 | $2.75억 | $8.49억 | $15.5억 | $15.2억 | |
| 매출채권 | $2.35억 | $3.86억 | $4.1억 | $6.34억 | $8.85억 | $11.4억 | $14.4억 | $15.6억 | $16.1억 | $20.5억 | |
| 재고자산 | $7760만 | $1.12억 | $1.24억 | $1.68억 | $2.81억 | $3.53억 | $4.61억 | $7.39억 | $12.1억 | $16.9억 | |
| 기타 유동자산 | $4780만 | $0 | $0 | $0 | $7970만 | $1.04억 | $1.22억 | $8610만 | $2.07억 | $7.49억 | |
| 유동자산 | $18.3억 | $26.5억 | $38.4억 | $48.2억 | $81.3억 | $95.6억 | $132억 | $141억 | $96억 | $112억 | |
| 유형자산(순액) | $6.98억 | $7.89억 | $8.12억 | $8.33억 | $12.8억 | $14.2억 | $14.6억 | $14.5억 | $25.8억 | $30.8억 | |
| 장기투자 | $2030만 | $2040만 | $0 | $0 | $0 | $0 | $1.12억 | $25억 | $51.1억 | $58.1억 | |
| 영업권 | $5040만 | $5040만 | $5040만 | $10억 | $10억 | $10억 | $10.9억 | $10.9억 | $10.9억 | $10.9억 | |
| 무형자산 | $2.84억 | $2900만 | $0 | $4억 | $4억 | $4억 | $6.04억 | $8.4억 | $8.26억 | $4.24억 | |
| 이연법인세자산 | $0 | $83.4만 | $15억 | $11.9억 | $8.83억 | $9.35억 | $12.5억 | $18.1억 | $23.3억 | $34억 | |
| 기타 비유동자산 | $1190만 | $695만 | $4070만 | $6940만 | $4930만 | $1.11억 | $4.1억 | $8.95억 | $9.99억 | $11.4억 | |
| 비유동자산 | $10.7억 | $8.97억 | $24억 | $35억 | $36.2억 | $38.7억 | $49.2억 | $85.9억 | $129억 | $149억 | |
| 자산총계 | $28.9억 | $35.5억 | $62.5억 | $83.2억 | $118억 | $134억 | $182억 | $227억 | $225억 | $261억 | |
| 부채 | |||||||||||
| 매입채무 | $6150만 | $7400만 | $1.11억 | $8760만 | $1.55억 | $1.95억 | $3.04억 | $3.65억 | $4.13억 | $4.62억 | |
| 미지급비용 | $2.68억 | $6.03억 | $8.15억 | $9.46억 | $11.4억 | $12.7억 | $17.9억 | $23.2억 | $3.52억 | $3.98억 | |
| 단기차입금 | $3억 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $9230만 | $8280만 | |
| 미지급세금 | $688만 | $0 | $0 | $7230만 | $1.04억 | $2.11억 | $1.23억 | $9950만 | $1.61억 | $0 | |
| 이연수익 | $7940만 | $2.38억 | $2490만 | $6230만 | $1.92억 | $1.72억 | $1.6억 | $1.7억 | $2.07억 | $1.72억 | |
| 기타 유동부채 | $1090만 | -$2.03억 | $2030만 | $2920만 | $8350만 | $1650만 | $6250만 | $5070만 | $25억 | $27.5억 | |
| 유동부채 | $7.93억 | $8.07억 | $11.2억 | $13.3억 | $18.8억 | $21.4억 | $27.4억 | $35.5억 | $35.6억 | $38.6억 | |
| 장기차입금 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $18.5억 | |
| 리스부채(비유동) | $5.21억 | $5.84억 | $5.82억 | $6.23억 | $8.9억 | $8.87억 | $8.1억 | $7.25억 | $16.6억 | $19.5억 | |
| 이연수익(비유동) | $8010만 | $7840만 | $8260만 | $8880만 | $0 | $0 | $0 | $0 | $0 | $0 | |
| 이연법인세부채 | $1.34억 | $634만 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $13.1억 | |
| 기타 비유동부채 | $3060만 | $2780만 | $2630만 | $1.87억 | $2.98억 | $3.03억 | $6.86억 | $8.78억 | $9.02억 | -$14.9억 | |
| 비유동부채 | $7.66억 | $6.96억 | $6.9억 | $8.98억 | $11.9억 | $11.9억 | $15억 | $16억 | $25.6억 | $36.2억 | |
| 부채총계 | $15.6억 | $15억 | $18.1억 | $22.3억 | $30.7억 | $33.3억 | $42.4억 | $51.5억 | $61.2억 | $74.8억 | |
| 자본 | |||||||||||
| 보통주 및 주식발행초과금 | $245만 | $251만 | $255만 | $259만 | $260만 | $250만 | $260만 | $260만 | $260만 | $250만 | |
| 이익잉여금 | -$53.7억 | -$51.2억 | -$29.9억 | -$18.5억 | $8.59억 | $32억 | $65.2억 | $101억 | $96.1억 | $136억 | |
| 기타포괄손익누계액 | $2120만 | -$1160만 | $65.9만 | -$197만 | -$6850만 | $1590만 | $80만 | -$1430만 | $1.28억 | -$1590만 | |
| 주주지분 | $11.6억 | $20.3억 | $44.4억 | $60.9억 | $86.9억 | $101억 | $139억 | $176억 | $164억 | $187억 | |
| 부채(차입) | |||||||||||
| 총차입금(리스 포함) | $8.41억 | $6.06억 | $5.87억 | $6.62억 | $9.32억 | $9.67억 | $9억 | $8.08억 | $17.5억 | $38.8억 | |
| 순차입금(차입금 - 현금) | -$3.43억 | -$10.6억 | -$20.6억 | -$24.5억 | -$50.6억 | -$58.3억 | -$96억 | -$95.6억 | -$28.2억 | -$12.1억 | |
Financial Modeling Prep이 기업의 제출 서류를 표준화한 데이터입니다. 지출과 비용은 제공처가 보고한 부호를 그대로 유지합니다. 기간에 마우스를 올리면 종료일이 표시됩니다. 금액 단위는 USD.
현금, 투자, 차입금
분기말다른 재무제표
출처
재무제표, 부문 매출, 지표, 추정치: Financial Modeling Prep. 부문별 이익과 전체 보고 항목: SEC EDGAR(XBRL). 참조한 제출 서류: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
데이터 기준일 2026-11-01